RNS Number : 9048J
Omega Diagnostics Group PLC
29 December 2020
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Update re AbC-19TM Rapid Test
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes today's update from
Abingdon Health plc (AIM: ABDX)
regarding the AbC-19TM Rapid Test and welcomes confirmation that they continue to work constructively with the Medicines and Healthcare products Regulatory Agency (MHRA) to try to enable approval for home use and self-test of the AbC-19TM Rapid Test in the UK.
Abingdon have also confirmed that whilst the DHSC continues to have first refusal for supplies of the AbC-19TM Rapid Test through a Supply of Goods Contract that extends to 14 February 2021, the UK-RTC is liaising with customers and regulatory authorities across a total of 27 international territories, to allow future use of the product outside of the UK.
Colin King, CEO of Omega Diagnostics, said:
"We welcome the update from Abingdon Health this morning and we look forward to being able to update investors on this approval process for self-test use in due course. We remain confident that the
AbC-19TM Rapid Test has a potential global application and we are delighted that the UK-RTC maintains constructive dialogue with interested customers and regulatory authorities across the world."
Contacts:
|
Omega Diagnostics Group PLC
|
Tel: 01259 763 030
|
|
Bill Rhodes, Interim Non-Executive Chairman
Colin King, Chief Executive
|
www.omegadiagnostics.com
|
|
Kieron Harbinson, Group Finance Director
|
|
|
|
|
|
finnCap Ltd
|
Tel: 020 7220 0500
|
|
Geoff Nash/Edward Whiley (Corporate Finance)
|
|
|
Alice Lane (ECM)
|
|
|
|
|
|
Walbrook PR Limited
|
Tel: 020 7933 8780 or
[email protected]
|
|
Paul McManus
|
Mob: 07980 541 893
|
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
[email protected] or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy.
END
NRAGZMZZMRZGGZZ